Health and Healthcare
Can Endocyte Survive Its Cancer Drug Implosion?
Published:
Last Updated:
Endocyte’s stock was halted Friday morning, after trading down more than 60% from the previous close of $17.38.
No safety concerns were raised about the drug, vintafolide, and Endocyte expressed surprise at the recommendation to halt the trial. The company said that it and Merck would review and validate the data before making a “formal decision regarding the execution of the trial.”
Endocyte recently closed a secondary offering that raised net proceeds of $101.8 million, and says it now has $233.3 million available in cash, cash equivalents and investments. The firm’s chief financial officer said that the company is “in a strong financial position to advance our next proprietary candidates through clinical development in multiple cancers.”
The company will continue to test vintafolide as a treatment for non-small-cell lung cancer, where the data is more favorable so far. Late-stage data from the tests is expected to be available later this year. The indications for the drug as a treatment for lung cancer is more important to Endocyte because the market for a lung cancer treatment is much larger. Merck may choose not to continue its participation in the lung cancer study, though, putting more pressure on Endocyte.
Endocyte shares traded down about 62%, at $6.68 in a 52-week range of $6.50 to $33.70. The low was set Friday.
ALSO READ: Did Endocyte Just Become Buyout Bait?
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.